Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215357 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
A Phase 2 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01215357 is a Phase 2 study that has completed, run by Emalex Biosciences. The registered enrollment target is 34 participants.
The verdict
NCT01215357, a Phase 2 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
Interventions
- DRUG Ecopipam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215357
The ClinicalTrials.gov registry entry for NCT01215357 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ecopipam is the first listed.
NCT01215357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215357 about?
NCT01215357 is a clinical study titled "Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble". This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
What is the current status of trial NCT01215357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2010-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01215357?
The interventions under investigation include: Ecopipam (DRUG).
Who is sponsoring clinical trial NCT01215357?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.